TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04818749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 12 mg
Description: Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg
Description: Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
Study: NCT06015399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of closed insufflation technique during segmentectomy
Description: After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of dilatation and collapse technique during segmentectomy
Description: Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
Study: NCT05574894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Growth hormone is supplemented during the ovarian stimulation till the day of trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist protocol for ovarian stimulation
Study: NCT05957042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Up to 4.8mL administered intravenously
Study: NCT05518253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT05125107

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG and dQFR/ds
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG and dQFR/ds
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG and dQFR/ds
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG and dQFR/ds
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)
Study: NCT06180759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of DMT
Description: A dose rate of 1.2 mg/min will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of ketamine
Description: A dose rate of 1.0 mg/min will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of placebo
Description: A Placebo (saline infusion) will be administered.
Study: NCT06036134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling Intervention
Description: In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Control Intervention
Description: The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
Study: NCT06079866

Intervention type: DEVICE
Group type: OTHER
Intervention: Mask A (Oran Park Mask) then Mask B (Evora Mask)
Description: Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Mask B (Evora Mask) then Mask A (Oran Park Mask)
Description: Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
Study: NCT05017714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant cytokine gene derived protein injection
Description: Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant cytokine gene derived protein injection
Description: Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Study: NCT05574894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist protocol for ovarian stimulation
Study: NCT04669717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1/d 500 mg Azithromycine Pfizer for 3 days
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics
Study: NCT06392204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate
Description: Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Champy's techqniue
Description: Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
Study: NCT05060432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inupadenant
Description: A2A receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inupadenant
Description: A2A receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inupadenant
Description: A2A receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inupadenant
Description: A2A receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody
Study: NCT05419570

Intervention type: OTHER
Intervention: Fluid Loading
Description: Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
Study: NCT04907071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)
Description: The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)
Description: The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)
Description: The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
Study: NCT05579210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online relapse prevention therapy
Description: Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face relapse prevention therapy
Description: Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
Study: NCT05894057

Intervention type: OTHER
Intervention: Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB
Description: On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.

Intervention type: OTHER
Intervention: Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB
Description: On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
Study: NCT05378412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3Cs
Description: The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
Study: NCT03939585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular therapy product
Description: Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.~* Infused using venous catheter on post-transplant Day 28 (+ 7 days).~* Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized).
Study: NCT05060432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC chemotherapies
Description: SOC chemotherapies in 1L mNSCLC
Study: NCT05476614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga (Robot-instructed)
Description: Yoga that is instructed by a social robot
Study: NCT06105866

Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid Annular Plane Systolic Excursion
Description: Transthoracic echocardiography will be performed on patients during hospitalization and preoperatively to investigate the relationship between preoperative fasting and right ventricular functions. This will be examined by looking at TAPSE
Study: NCT05992415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Using Patient Navigators
Description: Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Without Patient Navigators
Description: Consented participants referred from the 5 developments randomized to the Usual Care Arm 2 who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
Study: NCT05476614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga (Human-instructed)
Description: Yoga that is instructed by a human
Study: NCT04323020

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: CT Perfusion
Study: NCT05513586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Study: NCT04906252

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
Study: NCT06285149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
Study: NCT06145867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Description: deep red light therapy (670nm)
Study: NCT04966416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyrophosphate
Description: 50 mg/kg bwt once daily in gelatine capsules.
Study: NCT06333223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of (Poly)phenols and a probiotic supplement
Description: Mixture of (Poly)phenols and a probiotic supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Mixture of (Poly)phenols and a placebo maltodextrin comparator